Infection with Chlamydia pneumoniae as a cause of coronary heart disease: The hypothesis is still untested

Pathogens and Disease

Volumn 73, Issue 1, 2015, Pages

  Grayston, J Thomas ^a   Belland, Robert J ^b   Byrne, Gerald I ^b   Kuo, Cho Chou ^a   Schachter, Julius ^c   Stamm, Walter E ^a   Zhong, Guangming ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Antibiotic; Clinical trials; Treatment

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; CHILDHOOD; CHLAMYDIAL PNEUMONIA; CORONARY ARTERY ATHEROSCLEROSIS; DIAGNOSTIC PROCEDURE; FAMILY STUDY; HUMAN; HYPOTHESIS; INTRAVASCULAR ULTRASOUND; MEDICAL RESEARCH; NON INVASIVE PROCEDURE; NONHUMAN; NOTE; PATHOGENESIS; PRIORITY JOURNAL; RABBIT MODEL; ADOLESCENT; ADULT; AGED; ANIMAL; ATHEROSCLEROSIS; CHILD; CHLAMYDIA PNEUMONIAE; CHLAMYDOPHILA INFECTION; COMPLICATION; CORONARY DISEASE; FEMALE; INFANT; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ATHEROSCLEROSIS; CHILD; CHILD, PRESCHOOL; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CORONARY DISEASE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84938078016     PISSN: None     EISSN: 2049632X     Source Type: Journal    
DOI: 10.1093/femspd/ftu015     Document Type: Note

References (93)

1. Al-Marzooq F, Imad MA, HowSH, et al. Development ofmultiplex real-time PCR for the rapid detection of five bacterial causes of community acquired pneumonia. Trop Biomed 2011;28: 545-56.
2. Aldous MB, Grayston JT, Wang SP, et al. Seroepidemiology of Chlamydia pneumoniae TWAR infection in Seattle families, 1966-1979. J Infect Dis 1992;166:646-9.
3. Alpert BS, Collins RT. Assessment of vascular function: pulse wave velocity. J Pediatr 2007;150:219-20.
4. Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA 2005;293:2641-7.
5. Aoyama T, Chen M, Fujiwara H, et al. LOX-1 mediates lysophosphatidylcholine-induced oxidized LDL uptake in smooth muscle cells. FEBS Lett 2000;467:217-20.
6. Benedek TG. The history of bacteriologic concepts of rheumatic fever and rheumatoid arthritis. Sem Arthritis Rheu 2006;36:109-23.
7. Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. New Engl J Med 1998;338:1650-6.
8. Birck MM, Saraste A, Hyttel P, et al. Endothelial cell death and intimal foam cell accumulation in the coronary artery of infected hypercholesterolemic minipigs. J Cardiovasc Transl Res 2013;6:579-87.
9. Blessing E, Campbell LA, Rosenfeld ME, et al. A 6 week course of azithromycin treatment has no beneficial effect on atherosclerotic lesion development in apolipoprotein Edeficient mice chronically infected with Chlamydia pneumoniae. J Antimicrob Chemoth 2005;55:1037-40.
10. Blessing E, Campbell LA, Rosenfeld ME, et al. Chlamydia pneumoniae and hyperlipidemia are co-risk factors for atherosclerosis: infection prior to induction of hyperlipidemia does not accelerate development of atherosclerotic lesions in C57BL/6J mice. Infect Immun 2002a;70:5332-4.
11. Blessing E, Kuo CC, Lin TM, et al. Foam cell formation inhibits growth of Chlamydia pneumoniae but does not attenuate Chlamydia pneumoniae-induced secretion of proinflammatory cytokines. Circulation 2002b;105:1976-82.
12. Blessing E, Lin TM, Campbell LA, et al. Chlamydia pneumoniae induces inflammatory changes in the heart and aorta of normocholesterolemic C57BL/6J mice. Infect Immun 2000;68:4765-8.
13. Budrys NM, Gong S, Rodgers AK, et al. Chlamydia trachomatis antigens recognized in women with tubal factor infertility, normal fertility, and acute infection. Obstet Gynecol 2012;119:1009-16.
14. Bunk S, Susnea I, Rupp J, et al. Immunoproteomic identification and serological responses to novel Chlamydia pneumoniae antigens that are associated with persistent C. pneumoniae infections. J Immunol 2008;180:5490-8.
15. Camici PG, Rimoldi OE, Gaemperli O, et al. Non-invasive anatomic and functional imaging of vascular inflammation and unstable plaque. Eur Heart J 2012;33:1309-17.
16. Campbell LA, Kuo CC. Chlamydia pneumoniae-an infectious risk factor for atherosclerosis? Nat Rev Microbiol 2004;2:23-32.
17. Campbell LA, Lee AW, Rosenfeld ME, et al. Chlamydia pneumoniae induces expression of pro-atherogenic factors through activation of the lectin-like oxidized LDL receptor-1. Pathog Dis 2013. doi:10.1111/2049-632X.12058.
18. Campbell LA, Puolakkainen M, Lee A, et al. Chlamydia pneumoniae binds to the lectin-like oxidized LDL receptor for infection of endothelial cells. Microbes Infect 2012;14:43-9.
19. Campbell LA, Yaraei K, Van Lenten B, et al. The acute phase reactant response to respiratory infection with Chlamydia pneumoniae: implications for the pathogenesis of atherosclerosis. Microbes Infect 2010;12:598-606.
20. Cannon CP, Braunwald E, McCabe CH, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. New Engl J Med 2005;352:1646-54.
21. Chen M, Kakutani M, Minami M, et al. Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Arterioscl Throm Vas Biol 2000;20:1107-15.
22. Cho MC, Kim H, An D, et al. Comparison of sputum and nasopharyngeal swab specimens for molecular diagnosis of Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila. Ann Lab Med 2012;32:133-8.
23. Coombes BK, Mahony JB. cDNA array analysis of altered gene expression in human endothelial cells in response to Chlamydia pneumoniae infection. Infect Immun 2001;69:1420-7.
24. Daniel TM.Wade Hampton Frost and the index case concept. Int J Tuberc Lung D 2009;13:1345-6.
25. Dawber TR, Kannel WB, Lyell LP. An approach to longitudinal studies in a community: the Framingham Study. Ann NY Acad Sci 1963;107:539-56.
26. Diaz MH, Winchell JM. Detection of Mycoplasma pneumoniae and Chlamydophila pneumoniae directly from respiratory clinical specimens using a rapid real-time polymerase chain reaction assay. Diag Micr Infec Dis 2012;73:278-80.
27. Dowell SF, Peeling RW, Boman J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001;33:492-503.
28. Eitel J, Meixenberger K, van Laak C, et al. Rac1 regulates the NLRP3 inflammasome which mediates IL-1beta production in Chlamydophila pneumoniae infected human mononuclear cells. PLoS One 2012;7:e30379.
29. Ezzahiri R, Stassen FR, Kurvers HA, et al. Chlamydia pneumoniae infection induces an unstable atherosclerotic plaque phenotype in LDL-receptor, ApoE double knockout mice. Eur J Vasc Endovasc 2003;26:88-95.
30. Ezzahiri R, Nelissen-Vrancken HJ, Kurvers HA, et al. Chlamydophila pneumoniae (Chlamydia pneumoniae) accelerates the formation of complex atherosclerotic lesions in Apo E3-Leiden mice. Cardiovasc Res 2002;56:269-76.
31. Fong IW. Antibiotics effects in a rabbit model of Chlamydia pneumoniae-induced atherosclerosis. J Infect Dis 2000;181 (Suppl 3):S514-8.
32. Fong IW, Chiu B, Viira E, et al. De Novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbitmodel. Infect Immun 1999;67:6048-55.
33. Fong IW, Chiu B, Viira E, et al. Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model. Antimicrob Agents Ch 2002;46:2321-6.
34. Fox JP. Family-based epidemiologic studies. The second Wade Hampton Frost Lecture. Am J Epidemiol 1974;99:165-79.
35. Fox JP, Gelfand HM, Leblanc DR, et al. Studies on the development of natural immunity to poliomyelitis in Louisiana. I. Over-all plan, methods and observations as to patterns of seroimmunity in the study group. Am J Hyg 1957;65:344-66.
36. Gaydos CA. Growth in vascular cells and cytokine production by Chlamydia pneumoniae. J Infect Dis 2000;181 (Suppl 3):S473-8.
37. Gelfand HM, Leblanc DR, Fox JP, et al. Studies on the development of natural immunity to poliomyelitis in Louisiana. II. Description and analysis of episodes of infection observed in study group households. Am J Hyg 1957;65:367-85.
38. Goodrich JK, Di Rienzi SC, Poole AC, et al. Conducting a microbiome study. Cell 2014;158:250-62.
39. Grayston JT. Infections caused by C. pneumoniae strain TWAR. Clin Infect Dis 1992;15:757-61.
40. Grayston JT. Chlamydia pneumoniae (TWAR) infections in children. Pediatr Infect Dis J 1994;13:675-84.
41. Grayston JT.What is needed to prove that Chlamydia pneumoniae does, or does not, play an etiologic role in atherosclerosis? J Infect Dis 2000;181 (Suppl 3):S585-6.
42. Grayston JT, Kronmal RA, Jackson LA, et al. Azithromycin for the secondary prevention of coronary events. New Engl J Med 2005;352:1637-45.
43. Grayston JT, Wang SP, Yeh LJ, et al. Importance of reinfection in the pathogenesis of trachoma. Rev Infect Dis 1985;7:717-25.
44. Guzmann-Cottrill J, Jaggi P, Shulman S. Acute rheumatic fever: clinical aspects and insights into pathogenesis and prevention. Clin Appl Immunol Rev 2004;4:263-76.
45. Haidl S, Sveger T, Persson K. In: Orfila J, Byrne GI, Chernesky MA, et al. (eds). Longitudinal Pattern of Antibodies to Chlamydia Pneumoniae in Children. Bologna, Italy: Societa Editrice Esculapio, 1994, 189-92.
46. Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999;103:747-53.
47. Jackson LA, Campbell LA, Kuo CC, et al. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis 1997;176:292-5.
48. Juonala M, Magnussen CG, Venn A, et al. Influence of age on associations between childhood risk factors and carotid intimamedia thickness in adulthood: the Cardiovascular Risk in Young Finns Study, the Childhood Determinants of Adult Health Study, the Bogalusa Heart Study, and the Muscatine Study for the International Childhood Cardiovascular Cohort (i3C) Consortium. Circulation 2010;122:2514-20.
49. Kalayoglu MV, Byrne GI. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis 1998;177:725-9.
50. Kalayoglu MV, Hoerneman B, LaVerda D, et al. Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae. J Infect Dis 1999a;180:780-90.
51. Kalayoglu MV, Miranpuri GS, Golenbock DT, et al. Characterization of low-density lipoprotein uptake by murine macrophages exposed to Chlamydia pneumoniae. Microbes Infect 1999b;1:409-18.
52. Kataoka H, Kume N, Miyamoto S, et al. Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation 1999;99:3110-7.
53. Kaukoranta-Tolvanen SS, Teppo AM, Laitinen K, et al. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathogenesis 1996;21:215-21.
54. Korhonen JT, Olkkonen VM, Lahesmaa R, et al. ABC-cassette transporter 1 (ABCA1) expression in epithelial cells in Chlamydia pneumoniae infection. Microb Pathogenesis 2013;61-62:57-61.
55. Kothe H, Dalhoff K, Rupp J, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 2000;101: 1760-3.
56. Kume N, Murase T, Moriwaki H, et al. Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res 1998;83:322-7.
57. Kuo C, Campbell LA. Detection of Chlamydia pneumoniae in arterial tissues. J Infect Dis 2000;181 (Suppl 3):S432-6.
58. Kuo CC, Coulson AS, Campbell LA, et al. Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction. J Vasc Surg 1997;26: 29-31.
59. Kuo CC, Gown AM, Benditt EP, et al. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscl Throm 1993;13:1501-4.
60. Kuo CC, Grayston JT, Campbell LA, et al. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). P Natl Acad Sci USA 1995;92:6911-4.
61. Langille MG, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol 2013;31:814-21.
62. Li D, Liu L, Chen H, et al. LOX-1 mediates oxidized lowdensity lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation 2003;107:612-7.
63. Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDLmediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 2000;101:2889-95.
64. Liu W, He P, Cheng B, et al. Chlamydia pneumoniae disturbs cholesterol homeostasis in human THP-1 macrophages via JNKPPARgamma dependent signal transduction pathways. Microbes Infect 2010;12:1226-35.
65. Liuba P, Karnani P, Pesonen E, et al. Endothelial dysfunction after repeated Chlamydia pneumoniae infection in apolipoprotein Eknockout mice. Circulation 2000;102:1039-44.
66. Liuba P, Pesonen E, Paakkari I, et al. Acute Chlamydia pneumoniae infection causes coronary endothelial dysfunction in pigs. Atherosclerosis 2003;167:215-22.
67. McGill HC Jr, McMahan CA, Zieske AW, et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscl Throm Vas 2000;20:1998-2004.
68. Mamata Y, Hakki A, Newton C, et al. Differential effects of Chlamydia pneumoniae infection on cytokine levels in human T lymphocyte-and monocyte-derived cell cultures. Int J Med Microbiol 2007;297:109-15.
69. Moazed TC, Campbell LA, Rosenfeld ME, et al. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J Infect Dis 1999;180: 238-41.
70. Moazed TC, Kuo C, Grayston JT, et al. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis 1997;175:883-90.
71. Moriwaki H, Kume N, Kataoka H, et al. Expression of lectin-like oxidized low density lipoprotein receptor-1 in human and murine macrophages: upregulated expression by TNF-alpha. FEBS Lett 1998;440:29-32.
72. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998;97:633-6.
73. Netea MG, Kullberg BJ, Galama JM, et al. Non-LPS components of Chlamydia pneumoniae stimulate cytokine production through Toll-like receptor 2-dependent pathways. Eur J Immunol 2002;32:1188-95.
74. Netea MG, Selzman CH, Kullberg BJ, et al. Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. Eur J Immunol 2000;30: 541-9.
75. O'Connor CM, Dunne MW, Pfeffer MA, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 2003;290:1459-66.
76. Osika W, Dangardt F, Gronros J, et al. Increasing peripheral artery intima thickness fromchildhood to seniority. Arterioscl Throm Vas 2007;27:671-6.
77. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
78. Rothstein NM, Quinn TC, Madico G, et al. Effect of azithromycin onmurine arteriosclerosis exacerbated by Chlamydia pneumoniae. J Infect Dis 2001;183:232-8.
79. Sawamura T, Kume N, Aoyama T, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997;386:73-7.
80. She RC, Thurber A, Hymas WC, et al. Limited utility of culture for Mycoplasma pneumoniae and Chlamydophila pneumoniae for diagnosis of respiratory tract infections. J Clin Microbiol 2010;48:3380-2.
81. Song S, Jarvie T, Hattori M. Our second genome-human metagenome: how next-generation sequencer changes our life through microbiology. Adv Microb Physiol 2013;62: 119-44.
82. Sosnovik DE, Nahrendorf M, Weissleder R. Molecular magnetic resonance imaging in cardiovascular medicine. Circulation 2007;115:2076-86.
83. Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis 1989;9:I19-32.
84. Summersgill JT, Molestina RE, Miller RD, et al. Interactions of Chlamydia pneumoniae with human endothelial cells. J Infect Dis 2000;181 (Suppl 3):S479-82.
85. Tanaka K, Masuda J, Imamura T, et al. A nation-wide study of atherosclerosis in infants, children and young adults in Japan. Atherosclerosis 1988;72:143-56.
86. Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 2001;103:2705-10.
87. van Dijk EL, Auger H, Jaszczyszyn Y, et al. Ten years of nextgeneration sequencing technology. Trends Genet 2014;30: 418-26.
88. Volanen I, Jarvisalo MJ, Vainionpaa R, et al. Increased aortic intima-media thickness in 11-year-old healthy children with persistent Chlamydia pneumoniae seropositivity. Arterioscl Throm Vas 2006;26:649-55.
89. Wang J, Zhang Y, Lu C, et al. A genome-wide profiling of the humoral immune response to Chlamydia trachomatis infection reveals vaccine candidate antigens expressed in humans. J Immunol 2010;185:1670-80.
90. Watson C, Alp NJ. Role of Chlamydia pneumoniae in atherosclerosis. Clin Sci 2008;114:509-31.
91. Yoshida T, Koide N, Mori I, et al. Chlamydia pneumoniae infection enhances lectin-like oxidized low-density lipoprotein receptor (LOX-1) expression on human endothelial cells. FEMS Microbiol Lett 2006;260:17-22.
92. Zhao GJ, Mo ZC, Tang SL, et al. Chlamydia pneumoniae negatively regulates ABCA1 expression via TLR2-Nuclear factor-kappa B and miR-33 pathways in THP-1 macrophage-derived foam cells. Atherosclerosis 2014;235:519-25.
93. Zhu H, Xia M, Hou M, et al. Ox-LDL plays dual effect in modulating expression of inflammatory molecules through LOX-1 pathway in human umbilical vein endothelial cells. Front Biosci 2005;10:2585-94.